Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs

Troy Schwensen January 22, 2013

Free Research Reports on AMRN, FITB, PNC and SNE Issued by the Bedford Report

Marketwired January 18, 2013

Key to Success, How to Profit: MCP, FCX, AMRN and FB

Marketwired January 11, 2013

Amarin Announces Notification of Patent Allowance for U.S. Application 13/610,217 Related to Vascepa(R) and FDA Approved MARINE Indication

Troy Schwensen January 11, 2013

The Real Story Behind AMRN, MDBX, ALXA and DNDN

Marketwired January 7, 2013

Amarin to Present at the 31st Annual J.P. Morgan Healthcare Conference

Troy Schwensen January 2, 2013

Amarin Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier

Troy Schwensen January 2, 2013

Strategy Behind Our Success, We Get in Early: ARNA, AAPL, AMRN and HK

Marketwired December 31, 2012

Strategy Behind Our Success, We Get in Early: ALXA, RAD, AMRN and HLF

Marketwired December 28, 2012

Special Offer for Shareholders of ALXA, RAD, AMRN and HLF

Marketwired December 27, 2012

Secrets to Making Money in ALXA, RAD, AMRN and HLF

Marketwired December 26, 2012

The Straight Truth, Investing in AAPL, MCP, AMRN and SD

Marketwired December 21, 2012

Strategy Behind Our Success, We Get in Early: AAPL, MCP, AMRN and SD

Marketwired December 20, 2012